Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers.
- Author:
Kyungbin KIM
1
;
Won Young PARK
;
Jee Yeon KIM
;
Mee Young SOL
;
Dong Hun SHIN
;
Do Youn PARK
;
Chang Hun LEE
;
Jeong Hee LEE
;
Kyung Un CHOI
Author Information
1. Department of Pathology, Pusan National University Hospital, Pusan National University School of Medicine, Yangsan, Korea.
- Publication Type:Original Article
- Keywords:
Ovarian epithelial cancer;
Carbonic anhydrase IX;
GLUT-1;
Vascular endothelial growth factor A
- MeSH:
Anoxia;
Carbonic Anhydrases;
Glucose;
Humans;
Immunohistochemistry;
Mitosis;
Mucins;
Necrosis;
Neoplasms, Glandular and Epithelial;
Ovarian Neoplasms;
Recurrence;
Survival Rate;
Vascular Endothelial Growth Factor A
- From:Korean Journal of Pathology
2012;46(6):532-540
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Tumor hypoxia is associated with malignant progression and treatment resistance. Hypoxia-related factors, such as carbonic anhydrase IX (CA IX), glucose transporter-1 (GLUT-1), and vascular endothelial growth factor (VEGF) permit tumor cell adaptation to hypoxia. We attempted to elucidate the correlation of these markers with variable clinicopathological factors and overall prognosis. METHODS: Immunohistochemistry for CA IX, GLUT-1, and VEGF was performed on formalin-fixed, paraffin-embedded tissues from 125 cases of ovarian epithelial cancer (OEC). RESULTS: CA IX expression was significantly associated with an endometrioid and mucinous histology, nuclear grade, tumor necrosis, and mitosis. GLUT-1 expression was associated with tumor necrosis and mitosis. VEGF expression was correlated only with disease recurrence. Expression of each marker was not significant in terms of overall survival in OECs; however, there was a significant correlation between poor overall survival rate and high coexpression of these markers. CONCLUSIONS: The present study suggests that it is questionable whether CA IX, GLUT-1, or VEGF can be used alone as independent prognostic factors in OECs. Using at least two markers helps to predict patient outcomes in total OECs. Moreover, the inhibition of two target gene combinations might prove to be a novel anticancer therapy.
